| Patient | Howard Hughes |
|---|---|
| Date of birth | 1984-12-24 |
| Identifiers | MRN HR-ML006-SYN; SSN (made up) 000-06-5571 |
| Document date | 2026-07-13 |
| Author | Anselm Garrity-Moyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Ten-week review: sertraline dose, exposure therapy, his staff's part, hearing aids and pain. [S]
Mr. Hughes returns five weeks after his five-week review. The nurse called two weeks after the dose increase, and sertraline 100 mg has caused only mild sweating at night. His bronchitis from the sick visit cleared within three weeks without antibiotics. He has had nine exposure sessions in all, now twice weekly; he eats food his cook prepares without watching, and he has shaken hands twice at work. His assistant has attended two sessions, and the staff no longer wrap objects in tissue or wash before handing him things; he still asks for sealed milk bottles. Washing and checking take about two hours a day. He has used no opioid other than buprenorphine. Today, with his therapist waiting outside, he used the clinic bathroom and gave a urine sample. His hearing aids were fitted this morning. [S]
| Element | Detail |
|---|---|
| Rituals | About two hours a day; Y-BOCS 19 |
| Sertraline | 100 mg for five weeks; mild night sweats |
| Staff | Tissue-wrapping and the hand-washing rule for staff stopped |
| Buprenorphine | 8 mg twice daily; no other opioid use |
| Hearing aids | Fitted this morning |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Mild night sweats only; weight rising |
| Respiratory | Negative | Cough resolved |
| Musculoskeletal | Positive | Back and chest wall pain milder |
| Psychiatric | Positive | Contamination fears less intense; no thoughts of suicide or of harming anyone |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 300 mg with codeine 30 mg oral tablet, prescribed elsewhere since the crash as one or two tablets every 6 hours as needed, no more than 8 a day; he has been taking 10 to 12 a day | One or two tablets every 6 hours as needed, no more than 8 a day | Oral route | 2026-05-04 to 2026-05-11 | completed | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff | One spray as needed for suspected overdose; repeat in 2 to 3 minutes if needed | Nasal route | 2026-05-04 | active | S |
| Buprenorphine 2 mg with naloxone 0.5 mg sublingual film for the first day: 4 mg once withdrawal is moderate (COWS 12 or more), then 2 to 4 mg every one to two hours as needed, to no more than 16 mg on the first day | First-day induction by the written plan, no more than 16 mg | Sublingual route | 2026-05-11 to 2026-05-12 | completed | S |
| Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at first | One film under the tongue twice daily | Sublingual route | 2026-05-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped | Two tablets three times daily, no more than 3,000 mg a day | Oral route | 2026-05-11 | active | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-05-11 to 2026-06-08 | completed | S |
| Sertraline 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-08 to 2026-07-13 | completed | S |
| Sertraline 100 mg oral tablet, two tablets daily (200 mg), the usual target range for OCD | Two tablets daily | Oral route | 2026-07-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-13 | Body height | 191 | cm | S |
| 2026-07-13 | Body weight | 74.6 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 74 | /min | S |
| 2026-07-13 | Respiratory rate | 14 | /min | S |
| 2026-07-13 | Body temperature | 36.7 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-07-13 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 2026-07-13 | Mean score [PEG] | 4.7 | {score} | S |
Vital signs recorded on 2026-07-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 116/74, pulse 74; weight 74.6 kg, BMI 20.4 |
| Ears | Hearing aids in place; he follows conversation at normal volume |
| Respiratory | Clear |
| Psychiatric | Relaxed; shook hands on leaving; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Intrusive fears of contamination by germs for about a year, worse since the crash, with hand washing, cleaning of objects and avoidance of handshakes, shared spaces and food handled by others, taking about four hours a day; he recognizes the fears are probably excessive; cause under evaluation | resolved | confirmed | R46.81 | S — Synthetic presenting problem anchored to his documented fear of germs; resolved into the diagnosis of OCD at the consultation. Not a claim about his real symptoms in 1947. |
| Obsessive-compulsive disorder, contamination type, with good or fair insight, not tic-related; Y-BOCS 28 (severe) at intake; no post-traumatic stress disorder on screening | active | confirmed | F42.2 | S — Synthetic modern diagnosis made at the consultation, linked to the retrospective interpretation of his documented fears (R). Not a claim about his real diagnosis. |
| Opioid use disorder, moderate (four of the DSM-5-TR criteria that count for a prescribed opioid: taking more than prescribed, failed attempts to cut down, time spent getting prescriptions from two prescribers, and craving), on codeine prescribed after a crash; buprenorphine planned | active | confirmed | F11.20 | S — Synthetic modern coding; tolerance and withdrawal are not counted for a medicine taken under medical supervision. Person-first language; not a claim about his real diagnosis. |
| Chronic pain after major trauma ten months ago (crushed chest with rib fractures, collapsed lung, other fractures and burns): chest wall, left shoulder and low back pain, PEG 6.7 | active | confirmed | G89.21 | S — Synthetic modern diagnosis anchored to his documented injuries. |
| Difficulty hearing conversation, worse in noise, after years of flying in loud aircraft; cause under evaluation | resolved | confirmed | H91.93 | S — Synthetic presenting problem; resolved into a diagnosis when audiometry was done at five weeks. His documented deafness is from later years. |
| Bilateral high-frequency sensorineural hearing loss with a notch at 4000 Hz, consistent with noise exposure from flying; hearing aids fitted | active | confirmed | H90.3 | S — Synthetic modern diagnosis made at five weeks; not a claim about his real hearing in 1947. |
| Weight loss of about 8 kg since the crash (BMI 19.7), from eating little outside food he has prepared or inspected himself because of contamination fears | active | confirmed | R63.4 | S — Synthetic nutrition problem linked to the contamination fears; not a claim about his real weight in 1947. |
| Acute bronchitis, likely viral, for five days; no pneumonia on examination; resolved within three weeks without antibiotics | resolved | confirmed | J20.9 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | OCD severity (Y-BOCS, clinician-rated) and time spent on rituals | Every visit | Completed today | Y-BOCS 19; about two hours a day |
| Referral | Exposure and response prevention: sessions attended and home practice | Weekly, then twice weekly | Completed today | Nine sessions attended, now twice weekly |
| Medication safety | SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughts | Every visit, and two weeks after each start or dose change | Completed today | Nurse call two weeks after the last increase done; mild night sweats only; no activation; dose raised to 200 mg today |
| Self-management | Accommodation by staff, reduced step by step with his consent | Every visit | Completed today | His assistant attended two sessions; staff stopped wrapping objects and washing before handing him things |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and at least monthly during acute treatment | Completed today | PHQ-9 5, item 9 scored 0; GAD-7 8 |
| Survey | Suicide risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone |
| Self-management | Opioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation) | Every visit | Completed today | No cravings and no other opioid use |
| Laboratory | Urine drug test with fentanyl and buprenorphine, with consent | At start, then about monthly in the first months | Completed today | Collected today as a planned exposure: positive for buprenorphine, negative for fentanyl and other opioids |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's buprenorphine |
| Medication safety | Naloxone at home and household staff trained | Every visit | Completed today | Naloxone at home |
| Survey | Pain intensity and interference (PEG) and function | Every visit | Completed today | PEG 4.7 |
| Referral | Physical therapy and graded activity | Twice weekly, then weekly | Completed today | Moving to weekly sessions and a home program |
| Examination | Weight, meals and nutrition | Every visit | Completed today | 74.6 kg, up 2.6 kg since intake; three meals a day |
| Laboratory | Kidney function, liver enzymes and albumin | At baseline and at about six months on scheduled acetaminophen | Up to date | Next at about six months |
| Imaging | Hearing: audiometry, hearing aids and use | Audiometry once; hearing aid review after fitting | Completed today | Hearing aids fitted this morning |
Goal progress:
Guideline basis: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Prescription Drug Monitoring Programs (PDMPs) (2026); Hearing loss in adults: assessment and management (NG98) (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse telephone call in two weeks. Preventive visit in about two months. Twenty-two-week review in about twelve weeks with laboratory tests. Call the clinic or 988 at any time. Next scheduled visit 2026-09-14: periodic adult preventive visit. [S]